KR20260036616A - Glp1r 작용제의 치료적 용도 - Google Patents

Glp1r 작용제의 치료적 용도

Info

Publication number
KR20260036616A
KR20260036616A KR1020267006272A KR20267006272A KR20260036616A KR 20260036616 A KR20260036616 A KR 20260036616A KR 1020267006272 A KR1020267006272 A KR 1020267006272A KR 20267006272 A KR20267006272 A KR 20267006272A KR 20260036616 A KR20260036616 A KR 20260036616A
Authority
KR
South Korea
Prior art keywords
per day
phenyl
glp1r
agonist
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267006272A
Other languages
English (en)
Korean (ko)
Inventor
제니퍼 엘.알. 프리맨
마리아 카르멘 발카스 로페즈
Original Assignee
브이티브이 테라퓨틱스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브이티브이 테라퓨틱스 엘엘씨 filed Critical 브이티브이 테라퓨틱스 엘엘씨
Publication of KR20260036616A publication Critical patent/KR20260036616A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020267006272A 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도 Pending KR20260036616A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
US62/668,384 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists
KR1020207026027A KR20210005843A (ko) 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026027A Division KR20210005843A (ko) 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도

Publications (1)

Publication Number Publication Date
KR20260036616A true KR20260036616A (ko) 2026-03-17

Family

ID=66484210

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020267006272A Pending KR20260036616A (ko) 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도
KR1020207026027A Ceased KR20210005843A (ko) 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207026027A Ceased KR20210005843A (ko) 2018-05-08 2019-05-01 Glp1r 작용제의 치료적 용도

Country Status (9)

Country Link
US (2) US20210023072A1 (enExample)
EP (1) EP3790549A1 (enExample)
JP (2) JP2021523877A (enExample)
KR (2) KR20260036616A (enExample)
AU (2) AU2019266114A1 (enExample)
CA (1) CA3090823A1 (enExample)
MX (1) MX2020008387A (enExample)
SG (1) SG11202007966UA (enExample)
WO (1) WO2019217165A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221040A1 (es) 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
CA3168543A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4141008A4 (en) * 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
JP2023528565A (ja) * 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
US20230348412A1 (en) * 2020-05-28 2023-11-02 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Method for preparing glp-1 receptor agonist
TW202227455A (zh) * 2020-09-21 2022-07-16 美商維特衛治療有限責任公司 異喹啉衍生物的無定形形式
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r
KR102920994B1 (ko) 2024-05-20 2026-02-02 (주)인벤티지랩 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
KR101616737B1 (ko) 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 옥사디아조안트라센 화합물
CA2757084C (en) 2009-03-30 2017-08-29 Transtech Pharma, Inc. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
JP2015510947A (ja) * 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
WO2014113357A1 (en) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Also Published As

Publication number Publication date
AU2019266114A1 (en) 2020-08-27
US20210023072A1 (en) 2021-01-28
AU2025201814A1 (en) 2025-04-03
TW202015683A (zh) 2020-05-01
JP2021523877A (ja) 2021-09-09
WO2019217165A1 (en) 2019-11-14
JP2024112903A (ja) 2024-08-21
US20250325536A1 (en) 2025-10-23
EP3790549A1 (en) 2021-03-17
KR20210005843A (ko) 2021-01-15
SG11202007966UA (en) 2020-11-27
CA3090823A1 (en) 2019-11-14
MX2020008387A (es) 2020-12-11

Similar Documents

Publication Publication Date Title
US20250325536A1 (en) Therapeutic uses of glp1r agonists
JP6676108B2 (ja) ２型糖尿病の処置のためのリキシセナチド及びメトホルミン
DK2750699T3 (en) A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
KR20020050253A (ko) 항당뇨병 제제 및 치료방법
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
JP2015501314A (ja) ２型糖尿病の治療プロトコル
WO2008028914A1 (en) Combination treatment for diabetes mellitus
AU2014207748B2 (en) Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders
AU2025203014A9 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
Green et al. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm
TWI918593B (zh) Glp1r激動劑的治療用途
CN104582701B (zh) 减轻体重的方法
CN104487073A (zh) 改善肝功能的方法
DK182293B1 (en) Semaglutide for use in medical therapy including weight management
HK40131830A (zh) 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
Fonseca Pharmacological treatment of type 2 diabetes
Chaplin et al. Sitagliptin: first DPP‐4 inhibitor to treat type 2 diabetes

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000